Flash FinanceUS
Market open S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Profound Medical Corp. (PROF)

Profound Medical signs U.S. TULSA-PRO distribution deal with Cook Medical

Neutral Impact 3 of 5 product/contract Written later

Profound Medical's U.S. subsidiary appointed Cook Medical as a non-exclusive distributor of the TULSA-PRO system in the United States, for use with Cook's intraoperative MRI equipment. The filing does not disclose financial terms, and the initial five-year term does not start until FDA clearance for use with Cook's equipment is provided, so the deal's effect on shareholders depends on that clearance and on sales volumes.

Key points

  • Agreement dated October 28, 2026, effective October 23, 2026; Cook is a non-exclusive U.S. distributor of TULSA-PRO for use with Cook's iMRI equipment.
  • The five-year initial term begins on the date Profound provides Cook with written evidence of FDA clearance; Cook may terminate without liability if that has not occurred by April 30, 2027.
  • Cook will buy TULSA-PRO systems at a predetermined transfer price, while Profound keeps single-use disposables and service contract revenue from customers who buy through Cook.
  • The filing does not disclose purchase volumes, transfer prices or other dollar figures.

The filing

CompanyProfound Medical Corp. (PROF)
Form8-K, current report
Filed with the SECNov 3, 2026, 4:05 PM ET
Accession number0001104659-26-121980

Items reported: 1.01 Material Definitive Agreement7.01 Regulation FD Disclosure

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 8:53 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on November 03, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.